Monday was a positive day for the broad U.S. markets with all three major indices posting a solid gain to start the week. Although the averages performed well in the session, Crude…
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Wednesday include Applied Materials, Celgene, Children's Place, Kinder Morgan, Match, Myriad Genetics, Nordstrom and Oracle.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Thursday include AMAG Pharmaceuticals, Baidu, Cisco, General Electric, Honeywell, 3M, Salesforce.com, SunPower and United Technologies.
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
Paul Ausick 24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
